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The contribution of neuropeptide Y (NPY), deriving from adrenal
medulla, to the adrenosympathetic tone is unknown. We found
that in response to NPY, primary cultures of mouse adrenal chro-
maffin cells secreted catecholamine, and that this effect was
abolished in cultures from NPY Y1 receptor knockout mice (Y1).
Compared with wild-type mice (Y1), the adrenal content and
constitutive release of catecholamine were increased in chromaffin
cells from Y1 mice. In resting animals, catecholamine plasma
concentrations were higher in Y1mice. Comparing the adrenal
glands of both genotypes, no differences were observed in the
area of the medulla, cortex, and X zone. The high turnover of
adrenal catecholamine in Y1 mice was explained by the en-
hancement of tyrosine hydroxylase (TH) activity, although no
change in the affinity of the enzyme was observed. The molecular
interaction between the Y1 receptor and TH was demonstrated by
the fact that NPY markedly inhibited the forskolin-induced luciferin
activity in Y1 receptor-expressing SK-N-MC cells transfected with a
TH promoter sequence. We propose that NPY controls the release
and synthesis of catecholamine from the adrenal medulla and
consequently contributes to the sympathoadrenal tone.
adrenal gland  tyrosine hydroxylase  Y1 knockout mice
Neuropeptide Y (NPY) is a 36-aa peptide coreleased withnorepinephrine (NE) during sympathetic nerve activation (1,
2). NPY acts through differentG protein-coupled receptors termed
Y1, Y2, Y3, Y4, andY5 (3, 4). NPY is an important neurotransmitter
of the sympathetic function that potentiates the catecholamine
vasoconstrictor activity through theY1 receptor and exerts prejunc-
tional inhibitory effects on NE release from the sympathetic nerve
endings of the heart through the Y2 receptor (5). In addition, the
nerve terminals of parasympathetic neurons in the mouse heart
possess Y2 receptors, which, when activated, reduce acetylcholine
release, also causing an inhibition of the parasympathetic nervous
system (6). We have shown that NPY Y1 knockout mice (Y1)
lose their ability to potentiate NE-induced vasoconstriction and
have normal blood pressure, probably indicating a minor role of
NPY in the maintenance of blood pressure homeostasis (7). Re-
cently, thesemice were investigated for their cardiac sympathovagal
balance in baseline conditions and during an acute social challenge.
Reduced somatomotor activity during nonsocial challenges, lower
heart rate in baseline conditions, and larger heart rate responsive-
ness during social defeat were reported (8). Besides its presence in
nerve endings, NPY is produced by chromaffin cells of adrenal
medulla of different species, including human (9). The mouse has
higher adrenal NPY content than rat, pig, or humans (10, 11). The
effect of NPY on the adrenal medulla is controversial. NPY
stimulated catecholamine release from intact rat adrenal capsular
tissue (12), although an inhibitory effect of NPY on catecholamine
secretion in rat adrenomedullary primary cell cultures was also
observed (13). Moreover, there is a weak inhibitory effect of NPY
on NE and epinephrine (EP) release from bovine chromaffin cells,
evoked by addition of a cholinergic agonist (14, 15). However,
depending on the experimental conditions, conflicting results were
obtained. In perfused bovine adrenal gland, NPY stimulated the
secretion of catecholamine in the presence of cholinergic agonists
(14, 15). The exact subtype(s) of the NPY receptor(s) involved in
the modulation of bovine catecholamine secretion remain(s) un-
defined, although the presence of NPYY1 and the Y3 receptors has
been reported (16–18). In human chromaffin cells, we demon-
strated that NPY stimulates basal release of catecholamines
through a receptor that exhibits a Y3 pharmacological profile (9).
In the present study, we investigated the effect of NPY on
catecholamine release frommouse chromaffin cells. Using Y1
mice, we studied the changes resulting from the lack of the Y1
receptor on catecholamine release and synthesis from the mouse
adrenal gland. In addition, we compared baseline plasma NE and
EP concentrations in Y1mice with those in Y1 animals to
establish the contribution of the Y1 receptor on adrenal medulla
catecholamine synthesis in vivo.
Results
Plasma Catecholamine Concentrations. The baseline plasma NE and
EP concentrations were increased in Y1 compared with
Y1mice (Fig. 1). InY1mice, plasmaNEwas 4.3 0.9 nM
inmale and 3.3 0.3 nM in female and inY1mice, it was 2.8
0.4 nM in male and 2.4  0.7 nM in female (P  0.05 between
Y1 andY1). InY1mice, plasmaEPwas 1.1 0.2 nM
inmale and 1.4 0.6 nM in female, whereas in Y1mice, it was
0.6 0.1 nM inmale and 0.8 0.5 nM in female (P 0.05 between
Y1 and Y1). There was no difference between male and
female NE and EP plasma concentrations.
RT-PCR. We analyzed RNA isolated from mouse adrenal gland
obtained from three different mice for the presence of Y1, Y2, and
Y5mRNAs byRT-PCR, andwe detectedmRNA forY1,Y2, andY5
receptors in all samples (Fig. 2). In addition, we found that adrenal
glands fromY1mice expressY2 andY5 receptors (Fig. 9, which
is published as supporting information on the PNAS web site).
NE, EP, and NPY Contents of Mouse Adrenal Glands. The amount of
catecholamines (NEandEP) andNPYwasmeasured in the adrenal
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glands from female and male mice lacking the Y1 receptor
(Y1) compared with age-matched wild-type animals (Y1;
see Fig. 3). Adrenal glands from Y1 females contained 265
30 fmol NPY per microgram of protein, 23  1 pmol NE per
microgram of protein, 55  3 pmol EP per microgram of protein,
and adrenals from Y1 female mice contained 422  37 fmol
NPY per microgram of protein, 31 3 pmol NE per microgram of
protein, and 98  3 pmol EP per microgram of protein. In males,
the adrenals from Y1 contained 77  15 fmol NPY per
microgram of protein, 36 1 pmol NE per microgram protein, and
93 5 pmol EP per microgram of protein, whereas adrenals from
Y1 mice contained 180  22 fmol NPY per microgram of
protein, 66  5 pmol NE per microgram of protein, and 154  19
pmol EP per microgram of protein. Thus, adrenal contents in
catecholamines and NPY are always higher in Y1mice than in
Y1 animals. The adrenal glands from males contain more
catecholamines but less NPY compared with adrenals from female
mice when compared with their homologous genotype (Fig. 3). On
amolar basis, in control animals, adrenals frommales contain 1,675
times more catecholamine than NPY, whereas adrenals from
females contain 290 times more. In Y1 mice, adrenals from
males contain 1,222 times more catecholamine than NPY, whereas
adrenals from females contain 307 times more. The ratio of NE
reported to total catecholamine (NE  EP) in the adrenal glands
from males and females Y1 mice was similar at 29  2% and
27 1%, respectively. The same ratiowas observed inY1male
and female mice at 30  3% and 24  3%, respectively.
Constitutive and Regulated Release of NE and EP from Chromaffin
Cells from Y1 and Y1Mice.Wemeasured the spontaneous
release of NE and EP from chromaffin cells in vitro during 10min
and found that Y1 mice secreted a higher amount of
catecholamines than Y1 mice (Fig. 4). NE release was
0.52  0.09% of intracellular content in Y1 mice compared
with 2.3  0.4% in Y1 mice. EP release was 0.93  0.19%
of intracellular content in Y1 mice compared with 3.4 
0.5% in Y1 mice. When chromaffin cells were incubated
with nicotine (100M) for 10min (Fig. 4), there was a significant
increase in the release of NE and EP (17- and 4-fold increase,
respectively). However, nicotine was less potent to stimulate NE
and EP secretion from Y1 chromaffin cells (3- and 2-fold
increase for NE and EP, respectively).
Role of the Y1 Receptor in NPY-Induced NE and EP Release from Chro-
maffin Cells in Culture. To evaluate the effect of NPY on catechol-
amine secretion, we incubated chromaffin cells from Y1 mice
for 10 min with 100 nM NPY (Fig. 5) and observed an increase on
NE (1.3  0.21%) and EP (1.9  0.3%) release compared with
basal release (NE, 0.52 0.09; EP, 0.93 0.19%). The stimulatory
effect of the Y1Y5 agonist ([31Leu,34Pro]NPY 100 nM) or PYY
(100 nM)onNEandEP releasewas similar to the stimulatory effect
of NPY on chromaffin cells obtained from control animals (Fig. 5).
Fig. 3. NPY (A) and NE and EP (B) contents in adrenal gland of control
(Y1) and Y1 mice. Results (mean  SEM; n  6–8) are expressed as
pmol NE or EP (B) or fmol NPY (A) per microgram of protein. *, P  0.05; **,
P 0.01; ***, P 0.001 compared with adrenals of Y1mice; ##, P 0.01;
###, P  0.001 compared with adrenals from males.
Fig. 4. Basal and stimulated catecholamine (NE and EP) release from chro-
maffin cells obtained from adrenals of control mice (Y1) and Y1 knockout
mice (Y1). ***, P  0.001 compared with basal release from Y1
chromaffin cells; ###, P 0.001 compared with NE released with nicotine; †††,
P  0.001 compared with basal release from Y1 chromaffin cells.
Fig. 1. Plasma NE and EP concentrations are higher in Y1 compared with
Y1 mice. Plasma catecholamine was measured in seven or eight mice of
each gender and each genotype. *, P  0.05 compared with Y1 mice.
Fig. 2. Y1, Y2, and Y5 receptor mRNAs are present in a mouse adrenal gland
by RT-PCR. Similar findings were obtained in two additional adrenal glands.
Samples without RNA were included as negative controls (not shown).
10498  www.pnas.orgcgidoi10.1073pnas.0600913103 Cavadas et al.
However, 100 nM NPY did not increase NE and EP release from
chromaffin cells obtained from Y1 mice (Fig. 5), confirming
that secretory effect of NPY is mediated by the activation of the Y1
receptor.
Morphometric Analysis of Adrenal Glands from Y1 and Y1
Mice. No significant differences were observed in the area of the
adrenal medulla, cortex, and zone X of Y1 and Y1 mice
(Fig. 6A). Similarly, the number and the size of the cells were not
different between Y1 and Y1 mice in all areas of the
adrenal explored (Fig. 6B andC). Macroscopically, no lesions were
observed in Y1 mice. All adrenal glands analyzed were mi-
croscopically normal and revealed a normal architecture of the
cortex and the medulla. No nodule was observed. Cortical and
medullary cells presented no cytonuclear atypia.Nonecrosis and no
image of vascular invasion were observed. Therefore, the increase
of catecholamine content and release observed from the adrenal
medulla of Y1 mice is not associated with hypertrophy or
hyperplasia of the gland.
Tyrosine Hydroxylase (TH) Activity in Adrenal Glands from Y1 and
Y1 Mice. To determine the parameters of TH enzyme kinetics,
saturation curves using the substrate [L-3,4-dihydroxyphenylalanine
(L-DOPA)] were determined. Incubation of TH assay mixture
prepared from adrenals of wild-type or Y1 mice using the
substrate L-tyrosine (L-Tyr) resulted in a concentration-dependent
formation of L-DOPA (Fig. 7). We found that the Vmax values for
THactivity were significantly higher in the adrenals ofY1mice
compared with wild type, both in males and females (Fig. 7C; P 
0.01); Km values were not significantly different, indicating no
differences on TH affinity between the two genotypes. These
biochemical differences are consistent with a tight down-regulation
of TH synthesis through the activation of the Y1 receptor.
NPY Effect on TH Promoter Activity. To evaluate at the molecular
level the action of NPY on TH gene transcription, we transfected
the Y1-receptor-expressing cells SK-N-MC with a plasmid contain-
ing a 775-bp stretch of the rat TH promoter (774 to the CTG
initiation site). This stretch contained most transcription factor-
binding sites, including the AP1, the SP1, the POU Oct, the GRE,
and the two AP2 sites, as well as the cAMP response element
sequence (45 bp) that was shown to be the prime regulator of TH
transcription (19). Incubation of transfected cells for 6 h with
forskolin increased TH promoter-driven luciferase activity in a
concentration-dependent way (Fig. 8A). Maximal luciferase stim-
ulation was achieved with forskolin concentrations 10 M, and
the EC50 value was 1.43 0.089M.This effect was concentration-
dependently decreased when cells were incubated with NPY (Fig.
8B). Concentrations as low as 10 nMNPY inhibited EC50 forskolin-
induced luciferase activity by up to 70%, and IC50 was 1.50  0.47
nM (Fig. 8B). This effect was specific to the Y1 receptor, because
the Y1 antagonist BIBP3226 prevented TH promoter inhibition by
NPY (Fig. 8C). Whether NPY inhibitory effects were transient or
required long-lasting Y1 signaling was investigated by incubating
TH-transfected SK-N-MC cells with NPY for different periods
before and after forskolin stimulation. As shown in Fig. 8D, a weak
but significant inhibition of forskolin-induced TH promoter-driven
luciferase activity was achieved when cells were incubated with
NPY for up to 16 h before forskolin stimulation. However, maximal
inhibition was achieved when NPYwas present 1 h before forskolin
addition. Surprisingly, significant inhibitionwas also observedwhen
NPY was added 30 min after forskolin (Fig. 8D).
Whether forskolin-mediated increase in luciferase activity in
Fig. 5. NPY, PYY, and [31Leu,34Pro]NPY increase NE and EP release from
chromaffin cells obtained from control mice (Y1). The release of NE and
EP from mice chromaffin cells during 10 min in Krebs buffer (basal) or in the
presence of 100 nM NPY or PYY or [31Leu,34Pro]NPY was measured. Mean SD
of three to four experiments done in triplicate. P 0.05; **, P 0.01; ***, P
0.001 compared with basal.
Fig. 6. Morphometric analyses of adrenal glands from Y1 and Y1
mice: area of the medulla, cortex, and X zone (A); cell size (B); and number of
cells (C). Six mouse adrenals of each gender and genotype were analyzed. The
area of a series of sections performed in each gland was measured in triplicate.
The mean area of the largest section was evaluated.
Fig. 7. TH activity in adrenal glands from wild-type (Y1) and NPY Y1
knockout (Y1) mice. Saturation curves of TH activity obtained with the
substrate (L-Tyr) in the adrenals of males (A) and females (B) and Y1 and
Y1mice. (C) Kinetic parameters of saturation curves of TH activity in the
adrenals of male and female, Y1, and Y1mice. **, P 0.01 compared
with Y1; n  5; mean  SD.
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transfected cells is mediated by PKA or PKC was further investi-
gated by using specific inhibitors. As shown in Fig. 8E, the PKA
inhibitor H-89 inhibited luciferase activity60% at 2M, and IC50
was 1.50  0.47 M. In contrast, the PKC inhibitor calphostin C
(CalC) had only marginal effect, even at high concentrations (Fig.
8F). Concentrations 500 nM resulted in significant cell death
(results not shown). The additive inhibitory effect of these com-
pounds with NPY was evaluated. No further luciferase inhibition
was observed when cells were incubated with NPY  H-89 or
NPY  CalC, as compared with NPY alone.
Discussion
This study shows that the NPY-induced release of catecholamine
(NE and EP) from adrenal chromaffin cells is mediated by the
Y1 receptor, because NPY had no effect on catecholamine
release from the adrenal glands of mice lacking NPYY1 receptor
expression.
The effect of NPY is physiologically relevant, because a consti-
tutive release of NPY by the adrenal medulla appears to regulate
the secretion of catecholamine by an autocrine mechanism, as
shown with human adrenal chromaffin cells (6). Adrenal glands of
Y1 mice contain higher amounts of NE and EP than Y1
mice. This intracellular accumulation of NE and EP within chro-
maffin cells could be mediated by the lack of stimulation by NPY
on catecholamine secretion. Surprisingly, we observed the opposite,
because the accumulation of intracellular catecholamine in Y1
mice leads to a significant increase of NE and EP constitutive
release relative to their intracellular content. Thus, catecholamine
release is positively regulated by NPY, but it is still unclear how
Y1 mouse chromaffin cells, in addition to doubling their
catecholamine concentration, also release in baseline conditions
4-fold more than Y1 chromaffin cells. We hypothesized three
possibilities to explain these data: (i) an increase of chromaffin cell
number andor size in the adrenal gland, (ii) a deficiency of
catecholamine storage in chromaffin granules, or (iii) an increase of
catecholamine turnover rate. The first hypothesis was supported by
the increased catecholamine and NPY contents in the adrenals of
Y1mice, because a trophic effect of catecholamines, especially
NE, on the cardiovascular system has been demonstrated in several
studies (20–26). Also, NPY was shown to induce DNA synthesis in
a concentration-dependent manner and through the activation of
Y1 receptor in vascular smooth muscle cells (27–29), whereas in
cardiomyocytes, the trophic effect of NPY is mediated through Y5
receptors (30). Nevertheless, trophic actions of catecholamines
andor NPY do not explain the increased contents observed in the
adrenal glands of Y1 animals, because we did not observe an
increased cell number or size in those adrenals compared with
controls. That Y1 chromaffin cells in culture are less prone to
release catecholamine upon nicotinergic stimulation compared
with basal release might indicate a deficiency in vesicle storage or
an increased threshold for a depolarization event. However, this
hypothesis is unlikely, because the total amount of catecholamine
release induced by nicotine is similar in both genotypes. Therefore,
we further investigated the possibility of a molecular interaction
between NPY and catecholamine synthesis. Indeed, we found an
increase of TH activity with no change in the affinity of the enzyme
in the adrenals of Y1 mice. The effect of NPY on catechol-
amine synthesis by adrenal medulla has been observed but not
explained (31, 32). i.v. administration of NPY or a Y1 agonist
induced a marked increase of adrenal TH mRNA and TH protein
levels, whereas a Y2 receptor agonist was inactive (31, 32). On the
contrary, NPY inhibits depolarization-induced catecholamine syn-
thesis in rat pheochromocytoma cells (33). Interestingly, Bornstein
et al. (34) showed a marked increase of NPY mRNA and NPY
staining in chromaffin cells of adrenal glands in TH knockoutmice.
This suggests that the increase in NPY expression compensates for
the lack of catecholamine production. Because NPY and catechol-
amine expression and release are regulated by neural input to the
adrenal medulla, the increase in catecholamine as well as NPY
production may partially be the consequence of an increased
preganglionic stimulation of the chromaffin cells in both Y1 and
TH mice.
In the present study, we also show that NPY decreases the TH
promoter activity in Y1 receptor-expressing cells, SK-N-MC. The
Y1 antagonist, BIBP3226, prevents this effect. These results indi-
cate that NPY, in addition to controlling catecholamine release,
may also regulate NE and EP synthesis by acting directly on TH
expression. Indeed, activation of PKA with either forskolin or
cAMP analogs leads to a dramatic induction of THmRNAandTH
protein in many different cell types, including SK-N-MC cells
(35–40). This PKA-mediated response depends on the TH cAMP
response element (CRE; see refs. 35 and 41–44). The CRE
(position 45–38) site within the TH promoter is present in our
plasmid and may mediate, at least in part, the forskolin-triggered
TH promoter activation. In addition, both the CRE and AP1
(201–195) sites appear to mediate PKC-mediated TH promoter
activation (35, 45–49). Our observed impairment of forskolin-
Fig. 8. Inhibition of TH promoter activity by NPY. (A) SK-N-MC cells trans-
fected with a plasmid encoding the luciferase gene under the control of the
rat TH promoter were incubated for 6 h in the presence of the indicated
concentrations of forskolin, and luciferase activity was measured at different
times before and after the addition of NPY. A different cellular extract was
used at each time point. (B) Transfected SK-N-MC cells were incubated for 10
min with different concentrations of NPY and stimulated for 6 h with 1.25M
forskolin and luciferase, and activity was measured. (C) Effect of BIBP 3226 (1
M), a specific Y1 antagonist, on the NPY inhibitory effect of forskolin acti-
vation. (D) NPY (1.2 nM) was added before or after forskolin activation, and
luciferase activity was measured. SK-N-MC cells were incubated for 10 min
with NPY (1.2 nM) with or without H-89, a PKA inhibitor (E), or with or without
CalC, a PKC inhibitor (F), and forskolin activation and luciferase activity were
measured. Mean  SD; three to four experiments done in triplicate. ***, P 
0.001 compared with control. ###, P  0.001 compared with NPY; †††, P 
0.001 compared with the respective PK inhibitor.
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induced TH promoter activation by the PKA inhibitor, CalC,
further confirms the reported role of PKA-mediated cAMP-
dependent signaling in this process. In this context, the absence of
additive inhibitory effects of CalC and NPY may be explained by
the fact that the CRE-binding protein CREB was also shown to be
essential for the response of the TH promoter to PKA or PKC
activation (45, 46).
Phenylethanolamine-N-methyl transferase, the enzyme involved
in the methylation of NE into EP, is still able to ensure the
conversion ofNE intoEPproportionally to the increase in substrate
observed in Y1 mice, because we found a similar ratio of NE
reported to total catecholamine (NE  EP) in the adrenal glands
of males and females of both genotypes. This resulted in a higher
EP content and release from chromaffin cells in culture, contrib-
uting to an increase in the EP plasma levels in those mice. Because
EP is produced exclusively by the adrenal medulla, and a 40–50%
increase in plasma circulation of EP is observed in Y1 com-
paredwithY1mice, we estimated thatNPYcontributed to half
of the baseline catecholamine secretory activity of the mouse
adrenal medulla.
We observed differences between males and females in cate-
cholamine adrenal content. Adrenal glands from female mice
contain less catecholamine than those from males, as described in
rats (50). One possible explanation is that the adrenal medullary
content ofNEandEP in female rats is under the control of estrogen
(51). The paradoxical fact that catecholamine concentrations in
plasma are similar in males and females reflects differences in the
level of sympathetic activation, rate of synthesis, release, uptake,
andmetabolism. Indeed, the degradation of adrenal catecholamine
is also affected by sex hormones, and the levels of monoamine
oxidase and catechol-O-methyl transferase activity vary during the
oestral cycle (52). Those gender differences may also be a result of
differences in the clearance of released NE (i.e., neuronal and
extraneuronal uptake). An increase in adrenaline clearance in
women is suggested by a study that compared the effects of
exogenousEP inmen andwomen (53). Interestingly, adrenal glands
from female mice contain more NPY than those from males. It is
tempting to hypothesize that the higher NPY content of female
adrenal glands is due to a compensation of lower catecholamine
concentration.
Our results shed light on an important role of NPY that controls
catecholamine synthesis and secretion in the adrenal gland of mice,
by directly acting on TH expression. In conclusion, not only is NPY
a neurotransmitter, but it also may act as a hormone to finely tune
the adrenosympathetic tone.
Materials and Methods
Peptides and Chemicals. NPY1–36, [31Leu,34Pro]NPY and PYY
were purchased from Nova Biochem. The stock solution of fors-
kolin (Sigma) was 100 mgml in ethanol. The NPY stock solution
was 200 M in H2O. H-89 (a PKA inhibitor) and CalC (a PKC
inhibitor) were fromCalbiochem. Stock solutions (25 mM for H-89
and 0.8 mM for CalC) were prepared in dimethyl sulfoxide. FCS
was obtained from Seromed Biochrom, Berlin; and collagenase
type I, nicotine, and DNase were from Sigma. The Y1 antagonist,
BIBP3226 was a kind gift from K. Hofbauer (Novartis, Basel).
Animals. We used 3-mo-old male and female Y1 mice (7) and
their corresponding Y1 mice (C57BL6). They were back-
crossed for eight generations on a C57BL6 background (Iffa
Credo) by crossing homozygous Y1 with C57BL6 Y1
mice. Heterozygous mice were then crossed together to produce
homozygous mutants (Y1) and wild-type control littermates
(Y1).
Adrenal Gland and Chromaffin Cell Culture. Mice were manipulated
during 3 weeks and were killed by decapitation. Adrenal glands
were rapidly dissected out and flash-frozen in liquid nitrogen before
catecholamine and NPY assays. The cell culture was performed as
described (54). Briefly, freshly collected adrenal glands were
cleaned of fat tissue and digested in 1ml of a 0.3% collagenase type
I solution containing 0.02% DNase. The cells were cultured in 48
multiwell plates (75,000 chromaffin cells per well) and maintained
during 2–4 days at 37°C with 5% CO2. Cell viability, as determined
by trypan blue dye exclusion, was generally 95%.
RT-PCR. To determine the presence of NPY Y1, Y2, and Y5
receptors, totalRNAwas extracted from frozen adrenal glands, and
RT-PCR was carried out as described (30).
NE, EP, and NPY Quantification in Adrenal Glands. Adrenal glands
were sonicated in 0.4 M perchloric acid, and catecholamine was
extracted from the homogenate by adsorption on alumina, eluted
and separated by HPLC, and quantified by electrochemical detec-
tion (55). The NPY content in adrenal glands was determined after
sonication of the glands in Krebs buffer (111 mM NaCl2.5 mM
CaCl24.7 mM KCl1.2 mM MgSO41.2 mM KH2PO424.8 mM
NaHCO311.1 mM glucose15 mM Hepes, pH 7.4) with 0.08%
Tween 20 (Pierce) followed by centrifugation. NPY was measured
by ELISA (56). Results were expressed in fmol NPY or pmol NE
or EP per microgram of protein.
NE and EP Determination in Mouse Plasma. Mice were anesthetized
with halothane and underwent catheterization of the carotid artery
for blood sampling, heart rate, and bloodpressuremonitoring.Mice
were allowed to recover from anesthesia for 4 h, and 0.2ml of blood
was collected and centrifuged immediately at 2,000  g (57); this
method of blood collection is one of the less stressful for measuring
catecholamine in mice (57). Plasma was separated and frozen at
80°C until assayed. NE and EP in plasma were extracted on
alumina and measured by HPLC with electrochemical detection
(ED) (55).
Catecholamine Release Experiments in Mouse Chromaffin Cells. The
release experiments were performed as described (9). Briefly,
chromaffin cells were incubated for 10 min with Krebs buffer
(basal) or Krebs buffer with drugs. The released catecholamine in
supernatants wasmeasured byHPLC-ED andELISA, respectively.
Catecholamine release was expressed as the percent of total
catecholamine content in chromaffin cells.
Morphometric Analyses of Mouse Adrenal Glands. Adrenal glands
were carefully dissected,measured, weighed, and immersed in 4.5%
phosphate-buffered formalin (pH 7) and rinsed in PBS. During the
cutting step of the adrenals, all macroscopic lesions such as nodules,
areas of necrosis, hemorrhage, or cyst formation were analyzed. If
no macroscopic lesions were found, the gland was processed. All
samples were embedded in paraffin wax by using standardmethods.
Four-micrometer sections of the whole adrenals were made and
stained with hematoxylineosin. Morphometric analysis was per-
formed, and the area of a series of sections was measured in
triplicate for each section. The mean area of the largest section was
evaluated. The architecture of the adrenal cortex and medulla was
analyzed.
Determination of TH Activity. Twelve-week-old wild-type and
Y1mice were anesthetized with 60 mgkg pentobarbital. Left
and right adrenal glands were removed, fat was discarded, and they
were rapidly frozen at 80°C. TH activity was measured as
described (58). In brief, the adrenal gland was homogenized in 1.5
ml of a 0.25 M sucrose solution by using a glass homogenizer, and
an aliquot of 40l was used for eachTHassay. The reactionmixture
for the TH assay contained 0.1 M sodium acetate buffer (pH 6.0)
and 1 M 6-methyl-5, 6, 7, 8-tetrahydropterine (BH4) in 1 M
2-mercaptoethanol0.50 mM ferrous sulfate heptahydrate. In the
standard assay, 10-min incubation at 37°C was performed with a
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saturating concentration of substrate L-Tyr (100 M), and the
reaction was stopped with 300 l of 0.5 M perchloric acid. In the
blank incubation, L-Tyr was replaced by 100MD-Tyr, and 100M
3-iodo- L-Tyr, a TH inhibitor, was present. For TH kinetic analysis,
the same experimental conditions were used except for increasing
concentrations of either L-Tyr (10–400 M) or 6-methyl-5,6,7,8-
tetrahydropterine (50–1,600 M). The [L-3,4-dihydroxyphenylala-
nine (L-DOPA) formed in the reactionwasmeasured byHPLC-ED
after the alumina adsorptionmethod, as described (59). TH activity
was expressed as the amount of L-DOPA formed per milligram of
protein per hour.
Study of TH Promoter Activity. SK-N-MC cells (that express the Y1
receptor) were transfected with a plasmid encoding the firefly
luciferase gene under the control of a 775-bp stretch of the human
TH gene (774 to the CTG initiation site), a kind gift of Faucon
Biguet (Centre National de la Recherche Scientifique, Hoˆpital
Pitie´-Salpeˆtrie`re, Paris). Transfection was carried out by electro-
poration (10 g of plasmid for 5  106 cells) at 960 F and 280 V
in complete culture medium (DMEM supplemented with 10%
FCS10 mM Hepes1% nonessential amino acids) by using a
Bio-Rad GenePulser apparatus. This routinely resulted in 50–70%
transfected cells, as assessed by fluorescence (FACS) analysis of
cells electroporated under the same conditions with an EGFP-
encoding plasmid (not shown). Cells were washed and allowed to
recover for 24 h, then seeded (105 cells per well) in 48-well plates
in DMEM supplemented with 2% FCS. After 24 h, cells were
incubatedwith the test drugs. To preventNPYabsorption to plastic,
NPY solutions were prepared in DMEM supplemented with 0.2%
FCS and 0.0001%Tween-20. This medium onlymarginally (4–8%)
inhibited forskolin-induced TH luciferase activity (data not
shown). Determination of luciferase activity was performed by
using the luciferase kit (Promega) according to the manufacturer’s
recommendations.
Statistical Analysis. Statistical comparisons were performed by
ANOVA with the Bonferroni multiple comparison test.
We thank Dr. E. Potter (Prince of Wales Medical Research Institute,
Sydney) for the careful reading of the manuscript. This work was supported
by Fundac¸a˜o para a Cieˆncia e a Tecnologia (Portugal) Grants SFRHBD
103942002 and POCISAU-FCF603992004, Fundo Europeu de Des-
envolvimento Regional (Portugal), and Fonds National Suisse pour la
Recherche Grant 3100AO-101999.
1. Lundberg, J. M., Torssell, L., Sollevi, A., Pernow, J., Theodorsson Norheim, E.,
Anggard, A. & Hamberger, B. (1985) Regul. Pept. 13, 41–52.
2. Takiyyuddin,M. A., Brown,M. R., Dinh, T. Q., Cervenka, J. H., Braun, S. D., Parmer,
R. J., Kennedy, B. & O’Connor, D. T. (1994) J. Auton. Pharmacol. 14, 187–200.
3. Michel, M. C., Beck-Sickinger, A., Cox, H., Doods, H. N., Herzog, H., Larhammar,
D., Quirion, R., Schwartz, T. & Westfall, T. (1998) Pharmacol. Rev. 50, 143–150.
4. Silva, A. P., Cavadas, C. & Grouzmann, E. (2002) Clin. Chim. Acta 326, 3–25.
5. Walker, P., Grouzmann, E., Burnier, M. &Waeber, B. (1991) Trends Pharmacol. Sci.
12, 111–115.
6. Smith-White, M. A., Iismaa, T. P. & Potter, E. K. (2003) Br. J. Pharmacol. 140,
170–178.
7. Pedrazzini, T., Seydoux, J., Kunstner, P., Aubert, J. F., Grouzmann, E., Beermann,
F. & Brunner, H. R. (1998) Nat. Med. 4, 722–726.
8. Costoli, T., Sgoifo, A., Stilli, D., Flugge, G., Adriani, W., Laviola, G., Fuchs, E.,
Pedrazzini, T. & Musso, E. (2005) Neurosci. Biobehav. Rev. 29, 113–123.
9. Cavadas, C., Silva, A. P., Mosimann, F., Cotrim, M. D., Ribeiro, C. A., Brunner, H. R.
& Grouzmann, E. (2001) J. Clin. Endocrinol. Metab. 86, 5956–5963.
10. Allen, J. M., Adrian, T. E., Polak, J. M. & Bloom, S. R. (1983) J. Auton. Nerv. Syst.
9, 559–563.
11. Lundberg, J. M., Hokfelt, T., Hemsen, A., Theodorsson-Norheim, E., Pernow, J.,
Hamberger, B. & Goldstein, M. (1986) Regul. Pept. 13, 169–182.
12. Renshaw, D., Thomson, L. M., Carroll, M., Kapas, S. & Hinson, J. P. (2000)
Endocrinology 141, 169–173.
13. Shimoda, K., Shen, G. H., Pfeiffer, R. F., McComb, R. D. & Yang, H. Y. (1993)
Neurochem. Int. 23, 71–77.
14. Higuchi, H., Costa, E. & Yang, H. Y. (1988) J. Pharmacol. Exp. Ther. 244, 468–474.
15. Hexum, T. D. & Russett, L. R. (1989) Neuropeptides 13, 35–41.
16. Norenberg, W., Bek, M., Limberger, N., Takeda, K. & Illes, P. (1995) Naunyn-
Schmiedeberg’s Arch. Pharmacol. 351, 337–347.
17. Zheng, J., Zhang, P. & Hexum, T. D. (1997) Mol. Pharmacol. 52, 1027–1033.
18. Zhang, P., Zheng, J., Vorce, R. L. & Hexum, T. D. (2000) Regul. Pept. 87, 9–13.
19. Lewis-Tuffin, L. J., Quinn, P. G. & Chikaraishi, D. M. (2004)Mol. Cell Neurosci. 25,
536–547.
20. Abel, P. W., Trapani, A., Aprigliano, O. & Hermsmeyer, K. (1980) Circ. Res. 47,
770–775.
21. Chen, L., Xin, X., Eckhart, A. D., Yang, N. & Faber, J. E. (1995) J. Biol. Chem. 270,
30980–30988.
22. Zhang, H., Facemire, C. S., Banes, A. J. & Faber, J. E. (2002) Am. J. Physiol. 282,
H2364–H2370.
23. Jackson, C. L. & Schwartz, S. M. (1992) Hypertension 20, 713–736.
24. Erami, C., Zhang, H., Ho, J. G., French, D. M. & Faber, J. E. (2002) Am. J. Physiol.
283, H1577–H1587.
25. Johnson, M. D., Grignolo, A., Kuhn, C. M. & Schanberg, S. M. (1983) Life Sci. 33,
169–180.
26. van Kleef, E. M., Smits, J. F., De Mey, J. G., Cleutjens, J. P., Lombardi, D. M.,
Schwartz, S. M. & Daemen, M. J. (1992) Circ. Res. 70, 1122–1127.
27. Shigeri, Y. & Fujimoto, M. (1993) Neurosci. Lett. 149, 19–22.
28. Zukowska-Grojec, Z., Pruszczyk, P., Colton, C., Yao, J., Shen, G. H., Myers, A. K.
& Wahlestedt, C. (1993) Peptides 14, 263–268.
29. Erlinge, D., Brunkwall, J. & Edvinsson, L. (1994) Regul. Pept. 50, 259–265.
30. Pellieux, C., Sauthier, T., Domenighetti, A., Marsh, D. J., Palmiter, R. D., Brunner,
H. R. & Pedrazzini, T. (2000) Proc. Natl. Acad. Sci. USA 97, 1595–1600.
31. Hong, M., Li, S., Fournier, A., St-Pierre, S. & Pelletier, G. (1995)Neuroendocrinology
61, 85–88.
32. Erdem, S. R., Broxson, C. S., Erdem, A., Spar, D. S., Williams, R. T. & Tumer, N.
(2002) Neuropharmacology 43, 1280–1288.
33. McCullough, L. A. & Westfall, T. C. (1995) Eur. J. Pharmacol. 287, 271–277.
34. Bornstein, S. R., Tian, H., Haidan, A., Bottner, A., Hiroi, N., Eisenhofer, G.,
McCann, S. M., Chrousos, G. P. & Roffler-Tarlov, S. (2000) Proc. Natl. Acad. Sci.
USA 97, 14742–14747.
35. Kim, K. S., Park, D. H., Wessel, T. C., Song, B., Wagner, J. A. & Joh, T. H. (1993)
Proc. Natl. Acad. Sci. USA 90, 3471–3475.
36. Waymire, J. C., Weiner, N. & Prasad, K. N. (1972) Proc. Natl. Acad. Sci. USA 69,
2241–2245.
37. Lewis, E. J., Tank, A. W., Weiner, N. & Chikaraishi, D. M. (1983) J. Biol. Chem. 258,
14632–14637.
38. Tank, A. W., Curella, P. & Ham, L. (1986) Mol. Pharmacol. 30, 497–503.
39. Fossom, L. H., Sterling, C. R. & Tank, A. W. (1992) Mol. Pharmacol. 42, 898–908.
40. Kim, K. S., Tinti, C., Song, B., Cubells, J. F. & Joh, T. H. (1994) J. Neurochem. 63,
834–842.
41. Huang, Z. M., Thewke, D., Gong, Q. Q., Schlichter, D. & Wicks, W. D. (1991) Brain
Res. Mol. Brain Res. 11, 309–319.
42. Fung, B. P., Yoon, S. O. & Chikaraishi, D. M. (1992) J. Neurochem. 58, 2044–2052.
43. Best, J. A., Chen, Y., Piech, K.M. & Tank, A.W. (1995) J. Neurochem. 65, 1934–1943.
44. Tinti, C., Yang, C., Seo, H., Conti, B., Kim, C., Joh, T. H. & Kim, K. S. (1997) J. Biol.
Chem. 272, 19158–19164.
45. Piech-Dumas, K. M., Best, J. A., Chen, Y., Nagamoto-Combs, K., Osterhout, C. A.
& Tank, A. W. (2001) J. Neurochem. 76, 1376–1385.
46. Piech-Dumas, K. M. & Tank, A. W. (1999) Brain Res. Mol. Brain Res. 70, 219–230.
47. Icard-Liepkalns, C., Biguet, N. F., Vyas, S., Robert, J. J., Sassone-Corsi, P. & Mallet,
J. (1992) J. Neurosci. Res. 32, 290–298.
48. Nankova, B., Hiremagalur, B., Menezes, A., Zeman, R. & Sabban, E. (1996) Brain
Res. Mol. Brain Res. 35, 164–172.
49. Nagamoto-Combs, K., Piech, K. M., Best, J. A., Sun, B. & Tank, A. W. (1997) J. Biol.
Chem. 272, 6051–6058.
50. Lange, D. L., Haywood, J. R. & Hinojosa-Laborde, C. (1998) Hypertension 31,
403–408.
51. de Miguel, R., Fernandez-Ruiz, J. J., Hernandez, M. L. & Ramos, J. A. (1989) Life
Sci. 44, 1979–1986.
52. Fernandez-Ruiz, J. J., Bukhari, A. R., Martinez-Arrieta, R., Tresguerres, J. A. &
Ramos, J. A. (1988) Life Sci. 42, 1019–1028.
53. Lenders, J. W., De Boo, T., Lemmens, W. A., Reijenga, J., Willemsen, J. J. & Thien,
T. (1988) Am. J. Cardiol. 61, 1288–1291.
54. Cavadas, C., Silva, A. P., Cotrim,M.D., Ribeiro, C. A., Brunner, H. R. &Grouzmann,
E. (2002) Ann. N.Y. Acad. Sci. 971, 335–337.
55. Grouzmann, E., Werffeli-George, P., Fathi, M., Burnier, M., Waeber, B. & Waeber,
G. (1994) J. Clin. Endocrinol. Metab. 79, 1852–1856.
56. Grouzmann, E., Aubert, J. F., Waeber, B. & Brunner, H. R. (1992) Peptides 13,
1049–1054.
57. Grouzmann, E., Cavadas, C., Grand, D., Moratel, M., Aubert, J. F., Brunner, H. R.
& Mazzolai, L. (2003) Pflu¨gers Arch. 447, 254–258.
58. Moura, E., Pinho Costa, P. M., Moura, D., Guimaraes, S. & Vieira-Coelho, M. A.
(2005) Life Sci. 76, 2953–2964.
59. Soares-da-Silva, P., Pestana, M., Vieira-Coelho, M. A., Fernandes, M. H. & Albino-
Teixeira, A. (1995) Br. J. Pharmacol. 114, 1403–1413.
10502  www.pnas.orgcgidoi10.1073pnas.0600913103 Cavadas et al.
